Johnson & Johnson Covid-19 vaccines are seen on a table in Los Angeles, May 7, 2021.
Johnson & Johnson 's Janssen division, which helped to develop its single-dose COVID-19 vaccine, will close much of its vaccine research and development operations in the Netherlands, newspaper De Telegraaf reported.
In an emailed response on Wednesday, Johnson & Johnson confirmed plans to exit some of its vaccine research and development programs, which it said it had initially disclosed in its 2023 second-quarter results.
"We also continually assess our global footprint, including in the Netherlands, to ensure it meets our current and evolving scientific needs," Johnson & Johnson said.
De Telegraaf reported that 2,500 people worked at Janssen in the Netherlands, a quarter of which were in the section specialising in infectious diseases and vaccines.
Persons:
Johnson, Johnson Covid, Janssen, De Telegraaf
Locations:
Los Angeles, Netherlands